anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new useful pharmaceutical preparation or food capable of regulating immune balance.  &lt;P&gt;SOLUTION: The pharmaceutical preparation for regulating the immune balance comprising (B) at least one kind selected from lactulose or xylooligosaccharides in an amount of 1-20 pts.wt. based on (A) 1 pt.wt. of dead microbial cells of a lactic acid bacterium and containing 200,000,000,000 to 10,000,000,000,000 dead microbial cells of the lactic acid bacterium as a daily dose is provided. Furthermore, the food comprising (B) at least one kind selected from lactulose or xylooligosaccharides in an amount of 1-20 pts.wt. based on (A) 1 pt.wt. of the dead microbial cells of the lactic acid bacterium and containing 200,000,000,000 to 10,000,000,000,000 dead microbial cells of the lactic acid bacterium as the daily dose and having an indication that the food is used for regulating the immune balance is provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To provide the titled diagnostic agent containing insulin having ratioactive iodine atom in the molecule, as a main component, and useful for the diagnosis of cancer, its metastasis, or hepatic function including hyperglycemia by the determination of the distribution of the radioactivity in the body. CONSTITUTION:A nucleomedical radioactive diagnostic agent composed mainly of insulin containing radioactive iodine atom (e.g. &lt;123&gt;I, &lt;125&gt;I, &lt;131&gt;I) in the molecule. Various diseases such as cancer, its metastasis, or hepatic function disorder including hyperglycemia, etc. can be diagnosed by injecting the insulin labeled with the radioactive iodine, and inspecting the absorption and distribution of the radioactive iodine in the organs or tissues or the secretion of the radioactive insulin or its metabolite by a nucleomedical means. The introduction of the radioactive iodine in insulin is carried out by chloramine-T process or enzymatic process, etc., and its radioactivity is usually about 0.05-10mCi/ml.
ABSTRACT     A   chemical   composition  for   electrolytic   transdermal transport. of  a  protein  to the blood  stream  of  the  patient comprises: a) a protein, b) a cosolvent with negative Setschenow constants, and c) water.    Some  of  the preferred  proteins  are:  insulin,  protamine sulfate, calcitonin, glucagon,  and  corticotropin.   Some of the preferred dissociating agents with negative Setschenow  constants are:  urea, propylurea, potassium iodide, sodium perchlorate, and guanidine hydrochloride.    The electrolytic  device containing the composition  to  be transdermally delivered comprises: two electrode elements separated by barrier means, a   reservoir  containing  the  composition  of  the invention, an   electronic/electrolytic  circuit  including   a source of a power, a cover, and adhesive  means holding the device to the  patient&#39;s skin. A semipermeable membrane between the patient&#39;s skin and  the electrolytic device is optional.
Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two Neospora antigens- Neospora cyclophilin (NcCyP) and NcSRS2. The ability of native NcCyP to upregulate mouse IFNγ was also confirmed in this study. Recombinant NcCyP or NcSRS2 were tested either alone or in combination and formulated with adjuvant ImmuMax-SR and CpG. Female BALB/c mice (n=15) of 10-12 weeks of age were immunized s.c. twice in a 2-week interval with vaccines containing either NcCyP alone, NcSRS2 alone, NcCyP plus NcSRS2, or non-recombinant bacterial antigen (NR) in 2 separate trials. All mice were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Brain and serum were collected and Nc-specific DNA sequence in brain tissue and antibodies in serum were analyzed by PCR or ELISA/Westem blotting. Results showed that mice vaccinated with rNcCyP, rNcSRS2, or both rNcCyP and rNcSRS2 responded with high levels of NcCyP or NcSRS2 specific antibodies. Overall, mice received vaccines formulated with either rNcCyP or rNcCyP and rNcSRS2 had a higher (p&lt;0.01) percent protection when compared to the mock- or non-vaccinated mice. The groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection, which was higher (p&lt;0.05) than that of the non-vaccinated group but did not differ (p=0.06) from that of the mock-vaccinated group. The results of the present study indicate that NcCyP is a highly efficacious vaccine candidate which may be useful in protection against Neospora infection.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin having a preventing.improving effect not only on roughened skin of a healthy person or a person whose skin is susceptible to chapping but also on roughened skin symptom caused by various skin diseases such as cutaneous sensitization, psoriasis, etc., by formulating acid decomposition product of a specific polysaccharide. SOLUTION: An acid decomposition product of inulin is used. Chicory, sunchoke, burdock, elecampane, carduus, acetabularia, etc., are used as the raw material of inulin, especially the root of chicory is preferred. The acid decomposition product of the inulin is obtained, for example, by adding a strong acid such as hydrochloric acid, sulfuric acid, nitric acid, etc., to an inulin and allowing to acidify the inulin, etc. The preferable formulating amount of the inulin acid decomposition product is &gt;=0.005wt.% and &lt;=20.0wt.% of the preparation for external use for skin based on dried material. A UV absorber, a humectant, vitamins, anti-inflammatory agent, astringent drug, refrigerant, etc., are preferably formulated in this preparation for external use for skin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an immunoadjuvant that has high safety and enhances productivity of not only IgG associated with a systemic immunity but also secretory IgA associated with a topical infection protection mechanism of mucosa etc., and an immunoadjuvant dispersion and to provide a method for inoculating the same.  &lt;P&gt;SOLUTION: The immunoadjuvant contains chitosan microparticles. The dispersion contains the immunoadjuvant. The method for inoculating an immunoadjuvant comprises spraying the dispersion in the form of mist into animal lungs. The chitosan microparticles contained in the immunoadjuvant having a deacetylation degree of ≥60%, solution viscosity of 1 mass% of ≥1.5 mPa s and ≤1,000 mPa s and particle diameters of ≥0.5 μm and ≤20 μm are preferably used.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To prepare the titled drug containing, as a principal component, a polymer obtained by treating germanium dioxide with hypophosphorous acid, etc. in hydrogen halide, reacting with acrylic acid, dissolving the resultant compound in an organic solvent, and adding water to the solution. CONSTITUTION:A halogermanium phosphoric acid complex obtained by treating germanium dioxide with hypophosphorous acid or its salt in hydrohalogenic acid is made to react with acrylic acid to obtain the compound of formula I (X is halogen). The compound is dissolved in acetone or other organic solvent miscible with water, and the solution is added with water to obtain a water-soluble organic germanium polymer of formula II (n is integer of &gt;=3) or III. The polymer is used as a principal component of a drug for virus. It has extremely low toxicity, and can be administered orally or by injection or in the form of poultice in combination of various conventional substrates.
Described herein are compositions and methods that treat fungal infections of the skin, reduce the severity and duration of symptoms of fungal infections of the skin, and prevent recurrence of fungal infections. The topical compositions described herein are creamy pastes composed of an admixture of an imidazole antifungal and nystatin. The topical compositions can also include optional fillers. The compositions and methods described herein minimize fungal resistance and maximize the number of targeted fungal strains. Additionally, the compounds and methods do not suppress the body&#39;s immune system either locally or systemically, thus allowing for a faster restoration of normal skin flora. The compositions and methods described herein are particularly suitable for use in infants and children as well as in immunocompromised individuals, diabetics, and the obese.
A health club exercise records system in which members to the health club are given a handheld device that is pre-programmed by the trainer or health club operator to record different exercise activities. The handheld device includes a built-in numeric keypad, a display monitor, and optical reader designed to communicate with a compatible ID tag located on or in the vicinity of the exercise activity data source. Loaded into the working memory of the handheld device is a pre-programmed exercise data collection program. The exercise data collection program displays one or more sub-routines to the member requesting the member to input information regarding the exercise. The sub-routines are specific to the exercise activity data source and present one or more prompts requiring the member to input information. The inputted information is stored in a temporary data file located on the handheld device or transmitted immediately to a permanent member data file on a local server located in the health club. The system may also include an uplink terminal for transmitting the data in the temporarily data file to a remote server connected to a network operations center. A fitness tools software program is loaded into the server for collecting and processing the data in the member&#39;s permanent data file which may be reviewed by the trainer and/or member.
PURPOSE:To provide a substance effective in improving cholesterol metabolism and capable of increasing serum HDL-cholesterol level of human and animal without causing side effect, by heat-treating wheat bran at a specific temperature and using the product as an active component. CONSTITUTION:Wheat bran heated at &gt;=80 deg.C, preferably 95-200 deg.C is used as a substance for improving cholesterol metabolism. The heating is preferably carried out by using an extruder. It is preferably administered orally in the form of solid, however, it can be used as an additive of food (e.g. bread, cake, macaroni, noodle, etc.). It can be administered continuously over a long period at a high dose, preferably 10-30g without causing any problems nor lowering the original physiological activity such as prevention of constipation.
The present invention relates to a helically-shaped medicated veterinary system suitable for delivery of a drug to the vaginal cavity of a female non-human mammal and to a method of manufacture. The drug delivery system is helically-shaped and comprises a three layered polymer fibre. The polymer fibre comprises a polymer core, a polymer intermediate layer comprising a drug, and a polymer skin. The medicated system provides a controlled delivery of drug to the vaginal cavity of the mammal. The present invention also relates to a process of making the springs. ® KIPO &amp; WIPO 2009
Large-pore mesoporous silica nanoparticles (MSN) were prepared and functionalized to serve as a robust and biocompatible delivery platform for platinum-acridine (PA) anticancer agents. The material showed a high loading capacity for the dicationic, hydrophilic hybrid agent [PtCl(en)(N-[acridin-9-ylaminoethyl]-N-methylropionamidine)] dinitrate salt (P1 Al) and virtually complete retention of payload at neutral pH in a high-chloride buffer. In acidic media mimicking the pH inside the cells&#39; lysosomes, rapid, burst-like release of P1 A1 from the nanoparticles is observed. Coating of the materials in phospholipid bilayers resulted in nanoparticles with greatly improved colloidal stability. The lipid and carboxylate- modified nanoparticles containing 40 wt. % drug caused S phase arrest and inhibited cell proliferation in pancreatic cancer cells at submicromolar concentrations similar to carrier-free P1A1. One feature of the nanoparticle-delivered P1A1 was that the payload did not escape from the acidified lysosomal vesicles into the cytoplasm, but was shuttled to the nuclear membrane and released into the nucleus.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent a doctor from overlooking a disease other than a target of examination when the doctor reads the image of the target of examination and prepares a finding report.  &lt;P&gt;SOLUTION: PACS 30 performs an automatic measurement for medical image data and generates a numerical report information irrespective of a target of image reading by the doctor. A finding report generator 40 receives the numerical report information from the PACS 30. The finding report generator 40 automatically generates a finding report for the received numerical report information and generates finding report information. The finding report generator 40 transmits the finding report information to a distribution server 50.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare an oil gel cosmetic hardly damaging water retentivity at the administered site in its used form.  &lt;P&gt;SOLUTION: This oil gel cosmetic contains 10-80 mass% one or more kinds of oil components selected from phytosteryl hydroxystearate, a hydroxyalkyl hydroxy-dimer dilinoleyl ether, a fatty acid ester of dipentaerythritol, a tetraisostearic acid ester of sucrose, and dimer dilinoleyl dimer dilinoleate as the total based on the whole amount of the cosmetic. The cosmetic is preferably the one to be coated on a lip part. A lip color is preferable as the cosmetic to be coated on the lip part. The cosmetic reduces percutaneous perspiration of water in a coated state, and provides a cosmetic membrane formed therefrom having a large water content.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A method for facilitating medical admissions includes ascertaining an understood language, accessing a database on an electronic device configured to communicate with a patient, selecting a translation of a question, and communicating the translation to the patient. The patient provides a response to the question to a medical professional without a translator. A system for facilitating medical admissions includes a database of prerecorded question translations by medical professionals and response cues. Potential responses to a question are limited to predetermined choices. Trust ratings are associated with the translations. Response cues provide answers to the questions to be communicated to a medical professional without a translator. A system for facilitating medical admissions includes reference information and a database containing closed-ended questions and translations. The reference information includes a translating medical professional&#39;s expertise and fluent language. Each translation is provided by a medical professional and reviewed by other medical professionals.
The invention relates to tetracycline derivatives of formula &lt;FORM:1116686/C2/1&gt; wherein R-CO-NH is radical derived from tetracycline, OXY-, or chlor-tetracycline by removal of an amino hydrogen atom, &lt;FORM:1116686/C2/2&gt; is a diamino acid radical and -CO-R11 is a radical derived from an amino acid or oligopeptide of formula HOCO-R11. Diamino acids may be arginine, lysine or histidine, and the amino acid or oligopeptide is preferably of natural origin, e.g. carnosine.  The reaction is effected in an inert polar solvent, e.g. methanol or aqueous methanol by boiling the tetracycline with the oligopeptide in the presence of formaldehyde (Mannich&#39;s reaction).  An example is given for preparing tetracycline-methylene-carnosine.
The fatty acids, mainly chaulmoogric and hydnocarpic acids, obtained by saponification of the oils of flacourtiaceous seeds are purified by crystallization from alcohol and esterified with aliphatic, hydroaromatic or aromaticaliphatic alcohols to form the corresponding esters.  Reduction of these esters gives the corresponding mixed alcohols, which may then be treated with acylating agents to produce their acyl esters.  Flacourtiaceous plants mentioned are Taraktogenos kurzii, Hydnocarpus wightiana, Hydnocarpus anthelmintica, Carpotroche brasiliensis and Caloncoba echinata.  The products are useful therapeutically.  According to the examples, (1) the total fatty acids derived from the said oils are dissolved in hot alcohol and the crystalline acids which separate out on cooling are filtered off, washed with alcohol and dried; the mixed acids are then converted into their ethyl, cyclohexanyl, benzyl, thymyl, methyl and cinnamyl esters; (2) the ethyl esters of the mixed crystalline acids are reduced with sodium and alcohol; (3) the mixed alcohols prepared according to (2) are heated with benzoyl and cinnamoyl chlorides to give the corresponding esters.  Specifications 1984/09 and 311,236, [both in Class 2 (iii), Dyes &amp;c.], are referred to.
An aqueous composition including silica particles with a particle size distribution and particle structure that improve the water retention and exchange characteristics of the aqueous composition is provided. The aqueous silica composition includes silica network particles and water. The silica network particles comprise main particles and bridging particles that form chains between adjacent main particles. The main particles have a particles&#39; size greater than the particle size of the bridging particles. Because of the presence of the silica network particles, the aqueous composition is capable of wetting a hydrophobic substrate more than pure liquid water. The silica network particles are generated in water by a method in which an aqueous sodium silicate solution is subjected to vigorous agitation in air (17), followed by periods of circulation through magnetic fields of alternating direction (30) and further periodic agitation exposed to the air (60).
PROBLEM TO BE SOLVED: To prepare a physiologically active substance-containing tablet excellent in disintegrability in a mouth, good in flavor and having a low incidence of defectives and to provide a method for producing the tablet. SOLUTION: This physiologically active substance-containing tablet comprises at least the physiologically active substance and a hydrophilic sucrose ester of a fatty acid having &gt;=11 hyrophile-lipophile balance. The method for producing the tablet is obtained. As preferred modes, the hydrophilic sucrose ester of the fatty acid is composed of &gt;=60 wt.% of stearic acid and the ester of the hydrophilic sucrose ester of the fatty acid is &gt;=50 wt.% of a monoester. The physiologically active substance is a live bifidus bacterial powder and/or lactoferrins and the physiologically active substance is the live bifidus bacterial powder in an amount of 1×108 bacteria based on 1 g of the tablet or the physiologically active substance is the lactoferrins in an amount of at least 5 mg based on 1 g of the tablet.  Furthermore, the tablet comprises at least 0.1 wt.% of the sucrose ester of the fatty acid and at least 1-3 wt.% of a glycerol ester of the fatty acid.
PURPOSE:To delay the aging of human body, by taking poultry eggs having high iodine content as daily food. CONSTITUTION:An iodine compound and/or marine algae are added to the feed of poultry to an extent to exceed the normal iodine requirement of the poultry, and egg-laying poultry is fed with the feed to obtain eggs containing &gt;=300mug of iodine. The iodine compound is preferably calcium iodate in view of the health of the poultry and the transferability of iodine to the egg. The amount of iodine in the feed is adjusted to 50-2,500ppm, especially 50-150ppm. When an iodine compound is used in combination with marine algae, preferably 40-100ppm and 10-50ppm of the iodine are originated from the iodine compound and the marine algae, respectively. Daily use of the egg as a food prevents the hypothyroidism and arteriosclerosis, and reduces the contents of cholesterol and lipid peroxide in the brain.
This invention provides an isolated nucleic acid molecule which encodes a wildtype or mutated HOP-1. This invention also provides a purified wild-type HOP-1 protein or a purified mutated HOP-1 protein. This invention also provides a method for production of an antibody capable of binding to wild-type HOP-1 or mutated HOP-1 protein. This invention also provides an antibody capable of specifically binding to wild-type HOP-1 or mutated HOP-1. This invention also provides a transgenic animal comprising the isolated nucleic molecule encoding HOP-This invention also provides Caenorhabditis elegans mutants in the endogenous hop-1 gene and various method to produce such mutants. This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer&#39;s disease. This invention also provides a method for determining whether a compound is capable of ameliorating Alzheimer&#39;s disease. This invention also provides a method for producing suppressors of a hop-1 allele. This invention also provides a pharmaceutical composition effective in ameliorating Alzheimer&#39;s disease and methods of using such a pharmaceutical composition.
A novel molded article exhibiting a gradual disintegration effect is prepared with pullulan. The effect is imparted by incorporating heteromannan into a pullulan molded article in an amount not exceeding the weight of the pullulan used. Galactomannans (e.g. guar gum, tara gum, and locust bean gum) and glucomannans (e.g. konjak mannan) are feasible as the heteromannan. The molded article is advantageously usable for industrial materials, pharmaceuticals, consumers&#39; products, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a prophylactic agent and a therapeutic agent against botulinum toxin, a method for detecting botulinum toxin, and a botulinum toxin detection kit.  &lt;P&gt;SOLUTION: A polypeptide is provided which is derived from the heavy chain (H chain) of botulinum toxin produced by a genetic recombination technique. A vaccine (prophylactic agent) and an antibody (therapeutic agent) can be obtained from the obtained polypeptide. In type C or type D, it is most practicable to make a vaccine by mixing the C terminal side (Hc) of its heavy chain with HA1 (or HA3b) as part of its nontoxic component. A method for detecting botulinum toxin is also provided which comprises capturing that portion of a botulinum toxin complex which is other than the botulinum toxin light chain (L chain) and reacting the captured botulinum toxin light chain (L chain) with a substrate. A test kit is further provided which utilizes a nucleic acid amplification technique using a primer set common to the botulinum toxin genes of the respective types.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
NEW MATERIAL:A compound expressed by formula I (Z represents H or glucopyranosyl) and glycoside thereof. EXAMPLE:3,4&#39;,5-Trihydroxy-6,7-(methylenedioxy)flavone-3-glycoside expressed by formula II. USE:An anti-thrombin agent. PREPARATION:A lower aliphatic alcohol extract of an indigo is subjected to chromatography. The resultant fraction eluted by methanol is further subjected to chromatography and eluted by chloroform and methanol. The obtained eluate, if necessary, is chemically treated.
1,161,289. Stabilizing ascorbic acid. F. HOFFMANN-LA ROCHE &amp; CO. A.G. 21 June, 1968 [30 June, 1967], No. 29742/68. Heading C2V. Ascorbic acid and salts and esters thereof are stabilized by forming a coating by polymerizing a siloxane on individual particles of the ascorbic acid or ascorbic acid derivative. A solution of a siloxane in a volatile solvent is sprayed on the particles in a fluidized bed or the solution is mixed with the particles and then they are dried in a fluidized bed, the siloxane polymerizing as the particles are dried. Examples are given.